The absolute and relative incidences of ANPMD were higher among the patients with lysosomal storage diseases with skeletal abnormalities (66.7%), perlecan protein abnormalities (20%), FGFR3 chondrodysplasias (15%) and osteogenesis imperfecta/decreased bone density (13.2%), as shown in Table 1. This evidence concerns the gene FGFR3 and osteogenesis imperfecta.